Sales & Marketing News | pharmaphorum

News

AbbVie agrees $10.1bn deal to buy ImmunoGen

AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovar

News

FDA kicks off review of Karuna’s schizophrenia drug KarXT

Karuna Therapeutics said this morning that the FDA has formally started its review of KarXT, aiming to become the first drug to reach the market for schizophrenia with a n

News

CSL, Arcturus get first approval for self-assembling RNA jab

Japan’s medicines regulator has approved the first vaccine based on self-assembling RNA, a spin on the mRNA technology used in current shots, which is designed to deliver greater effi

News

FDA launches wide probe into CAR-T therapy safety

The FDA has announced it will start an investigation into the safety of CAR-T therapies, after becoming concerned that they may be linked to the development of T-cell canc

News

FDA okays first therapy for desmoid tumours from SpringWorks

Pfizer spin-out SpringWorks Therapeutics has its first approved product after getting a green light from the FDA for Ogsiveo, the first-ever therapy for a rare type of non

News

EVERSANA brings GenAI to medical content approvals

EVERSANA’s alliance with Amazon Web Services (AWS) on the application of generative artificial intelligence (GenAI) to the pharma sector has borne its first fruit – a new

AbbVie agrees $10.1bn deal to buy ImmunoGen

FDA kicks off review of Karuna’s schizophrenia drug KarXT

CSL, Arcturus get first approval for self-assembling RNA jab

FDA launches wide probe into CAR-T therapy safety

FDA okays first therapy for desmoid tumours from SpringWorks

EVERSANA brings GenAI to medical content approvals

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks